TW200927170A - Anti-factor B antibodies and their uses - Google Patents

Anti-factor B antibodies and their uses Download PDF

Info

Publication number
TW200927170A
TW200927170A TW097143224A TW97143224A TW200927170A TW 200927170 A TW200927170 A TW 200927170A TW 097143224 A TW097143224 A TW 097143224A TW 97143224 A TW97143224 A TW 97143224A TW 200927170 A TW200927170 A TW 200927170A
Authority
TW
Taiwan
Prior art keywords
antibody
factor
fragment
sequence
ser
Prior art date
Application number
TW097143224A
Other languages
English (en)
Chinese (zh)
Inventor
Lookeren Campagne Menno Van
Laura Deforge
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200927170(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of TW200927170A publication Critical patent/TW200927170A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW097143224A 2007-11-08 2008-11-07 Anti-factor B antibodies and their uses TW200927170A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US264807P 2007-11-08 2007-11-08

Publications (1)

Publication Number Publication Date
TW200927170A true TW200927170A (en) 2009-07-01

Family

ID=40344464

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097143224A TW200927170A (en) 2007-11-08 2008-11-07 Anti-factor B antibodies and their uses

Country Status (15)

Country Link
US (4) US8158762B2 (OSRAM)
EP (1) EP2209807A1 (OSRAM)
JP (1) JP2011503094A (OSRAM)
KR (1) KR20100105587A (OSRAM)
CN (1) CN101918444A (OSRAM)
AR (1) AR069233A1 (OSRAM)
AU (1) AU2008323939A1 (OSRAM)
BR (1) BRPI0820343A2 (OSRAM)
CA (1) CA2704973A1 (OSRAM)
CL (1) CL2008003313A1 (OSRAM)
IL (1) IL205577A0 (OSRAM)
MX (1) MX2010005115A (OSRAM)
PE (1) PE20091022A1 (OSRAM)
TW (1) TW200927170A (OSRAM)
WO (1) WO2009061910A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI407953B (zh) * 2011-03-24 2013-09-11 Univ Kaohsiung Medical 用於調節補體因子ｂ（ｃｆｂ）表現的醫藥組合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01699B (me) 2009-07-02 2014-09-20 Musc Found For Res Dev Metode za stimulaciju regeneracije jetre
EP2855529A4 (en) * 2012-05-24 2015-12-09 Alexion Pharma Inc HUMANIZED ANTI-FACTOR B ANTIBODIES
SG10202012791TA (en) 2013-11-15 2021-01-28 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
TN2018000341A1 (en) 2016-04-04 2020-06-15 Bioverativ Usa Inc ANTl-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF.
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
KR20230004686A (ko) 2020-04-20 2023-01-06 젠자임 코포레이션 인간화 항-보체 인자 Bb 항체 및 그의 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
US7999082B2 (en) * 2004-02-10 2011-08-16 National Jewish Medical And Research Center Anti-factor B antibodies
SI2500030T2 (sl) * 2005-11-04 2018-11-30 Genentech, Inc. Uporaba inhibitorjev komplementarnih procesov za zdravljenje očesnih bolezni
DK1991275T3 (en) 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
JP5332064B2 (ja) 2007-03-01 2013-11-06 ウェルスタット イムノセラピューティクス， エルエルシー 炎症により特徴付けられる疾患の治療

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI407953B (zh) * 2011-03-24 2013-09-11 Univ Kaohsiung Medical 用於調節補體因子ｂ（ｃｆｂ）表現的醫藥組合物

Also Published As

Publication number Publication date
CA2704973A1 (en) 2009-05-14
CL2008003313A1 (es) 2010-02-05
WO2009061910A1 (en) 2009-05-14
PE20091022A1 (es) 2009-07-16
BRPI0820343A2 (pt) 2017-08-22
CN101918444A (zh) 2010-12-15
US8158762B2 (en) 2012-04-17
US20090123469A1 (en) 2009-05-14
AR069233A1 (es) 2010-01-06
US20180037667A1 (en) 2018-02-08
KR20100105587A (ko) 2010-09-29
AU2008323939A1 (en) 2009-05-14
US20120230997A1 (en) 2012-09-13
EP2209807A1 (en) 2010-07-28
US20160024224A1 (en) 2016-01-28
JP2011503094A (ja) 2011-01-27
MX2010005115A (es) 2010-05-27
IL205577A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
TWI419704B (zh) 預防及治療與補體相關之眼部病症
TWI441832B (zh) Ｃ３ｂ抗體及預防及治療補體相關疾病之方法
US20180037667A1 (en) Anti-factor b antibodies and their uses
CN111995681A (zh) 抗tigit的抗体、其制备方法和应用
JP2021520195A (ja) Ｃ３結合薬及びその使用方法
AU2017254945A1 (en) Prevention and treatment of complement-associated eye conditions
AU2013213753A1 (en) Prevention and treatment of complement-associated eye conditions